Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate

Antiviral Therapy

Volumn 19, Issue 5, 2014, Pages 511-519

  Bifano, Marc ^a   Sevinsky, Heather ^a   Hwang, Carey ^a   Kandoussi, Hamza ^a   Jiang, Hao ^a   Grasela, Dennis ^a   Bertz, Richard ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; DRUG METABOLITE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; NORELGESTROMIN; NORGESTREL; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; NORGESTIMATE, ETHINYL ESTRADIOL DRUG COMBINATION; ORAL CONTRACEPTIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MULTIPLE CYCLE TREATMENT; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; TREATMENT DURATION; VOLUNTEER; ADOLESCENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG INTERACTION; DRUG MONITORING; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; ETHINYL ESTRADIOL; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMIDAZOLES; NORGESTREL; YOUNG ADULT;

EID: 84924293707     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2718     Document Type: Article

References (33)

1. Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int 2011; 31:1-3.
2. Armstrong GL, Wasley A, Simard E.P., McQuillan GM, Kuhnert WL, Alter MJ The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-714.
3. Hadziyannis SJ, Sette H Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
4. Ghany MG, Nelson DR, Strader D.B., Thomas DL, Seeff LB An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-1444.
5. Druyts E, Mills EJ, Nachega J, O'Regan C, Cooper CL Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. Clin Exp Gastroenterol 2012; 5:11-21.
6. Jacobson IM, McHutchison JG, Dusheiko G, et al Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
7. Poordad F, McCone J, Bacon B.R., et al Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
8. Victrelis (boceprevir). Package insert 2012. Merck & Co., Inc., NJ, USA.
9. Incivek (telaprevir). Package insert 2012. Vertex Pharmaceuticals Incorporated, MA, USA.
10. Wilby KJ, Greanya ED, Ford J.A., Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012; 11:179-185.
11. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P., Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54:20-27.
12. Hirai S, Hussain A, Haddadin M., Smith RB First-pass metabolism of ethinyl estradiol in dogs and rats. J Pharm Sci 1981; 70:403-406.
13. Guengerich FP. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 1988; 33:500-508.
14. Wang B, Sanchez RI, Franklin R.B., Evans DC, Huskey SE The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos 2004; 32:1209-1212.
15. Ebner T, Remmel RP, Burchell B. Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol. Mol Pharmacol 1993; 43:649-654.
16. Bukh J, Pietschmann T, Lohmann V., et al Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci US 2002; 99:14416-14421.
17. Lindenbach BD, Rice CM Unravelling hepatitis C virus replication from genome to function. Nature 2005; 436:933-938.
18. Gao M, Nettles RE, Belema M, et al Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465:96-100.
19. Pol S, Ghalib RH, Rustig V.K., et al Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012; 12:671-677.
20. Everson GT, Sims KD, Rodriguez-Torres M, et al Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014; 146:420-429.
21. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370:211-221.
22. Chayama K, Takahashi S, Toyota J., et al Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55:742-748.
23. Lok AS, Gardiner D F, Lawitz E, et al Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366:216-224.
24. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Accessed 8 June 2012). Available from http://aidsinfo.nih.gov/guidelines
25. Zhang J, Chung E, Yones C., et al The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther 2011; 16:157-164.
26. Sekar VJ, Lefebvre E, Guzman S.S., et al Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. Antivir Ther 2008; 13:563-569.
27. Sonoda J, Xie W, Rosenfeld J.M., Barwick JL, Guzelian PS, Evans RM Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc Natl Acad Sci U S A 2002; 99:13801-13806.
28. Luo G, Cunningham M, Kim S., et al CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002; 30:795-804.
29. Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998; 32:554-563.
30. Davis AR, Westhoff CL, Stanczyk FZ Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. Epilepsia 2011; 52:243-247.
31. Garg V, van Heeswijk R, Yang Y, Kauffman R., Smith F, Adda N. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir. J Clin Pharmacol 2012; 52:1574-1583.
32. Royal College of Obstetricians and Gynaecologists. Faculty of Sexual And Reproductive Healthcare clinical guidance. Drug interactions with hormonal contraception: clinical effectiveness unit. (Updated January 2012. Accessed October 2013.) Available from http://www.fsrh.org/pdfs/CEUguidancedruginteractionshormonal.pdf
33. Nettles RE, Gao M, Bifano M., et al Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011; 54:1956-1965.